Accordingly, genetic or pharmacological inhibition of FASN has been found to increase MHC-I (also called HLA-I) levels in hepatocellular carcinoma (HCC), promoting antigen presentation and stimulating antigen-specific CD8 + T-cell cytotoxicity [18]. This evidence concerns the gene CD8A and hepatocellular carcinoma.